Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04506554 · ClinicalTrials.gov registry record · Phase 2
A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
A Phase 2 study of Muscle-Invasive Bladder Carcinoma, sponsored by Fox Chase Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 4
- Study locations
NCT04506554 is a Phase 2 study of Muscle-Invasive Bladder Carcinoma that is active but no longer recruiting, run by Fox Chase Cancer Center. The registered enrollment target is 81 participants, below the 120-participant average among 14 other Muscle-Invasive Bladder Carcinoma trials with a reported enrollment target (32% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT04506554, a Phase 2 study of Muscle-Invasive Bladder Carcinoma, is active but no longer recruiting, sponsored by Fox Chase Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 4
- Study locations
Study Summary
Neoadjuvant accelerated methotrexate/vinblastine/adriamycin/cisplatin (AMVAC) in combination with nivolumab is under evaluation for the treatment of muscle invasive bladder cancer (MIBC). Patients with pre-specified tumor mutations and complete clinical response with neoadjuvant therapy will preserve their bladders and go on active surveillance.
Conditions Studied
Interventions
- DRUG AMVAC + Nivolumab
Study Locations (4)
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
- Fox Chase Cancer Center - Philadelphia - Philadelphia
North Carolina
- UNC Lineberger Comprehensive Cancer Center - Chapel Hill
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2028-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04506554
The ClinicalTrials.gov registry entry for NCT04506554 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 120-participant average among 14 other Muscle-Invasive Bladder Carcinoma trials with a reported enrollment target (32% lower). The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Muscle-Invasive Bladder Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which AMVAC + Nivolumab is the first listed.
NCT04506554 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Pennsylvania, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT04506554 about?
NCT04506554 is a clinical study titled "A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer". Neoadjuvant accelerated methotrexate/vinblastine/adriamycin/cisplatin (AMVAC) in combination with nivolumab is under evaluation for the treatment of muscle invasive bladder cancer (MIBC). Patients with pre-specified tumor mutations and complete clinical response with neoadjuvant therapy will preserv...
What is the current status of trial NCT04506554?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2020-12-01. Estimated completion is 2028-11.
What conditions does trial NCT04506554 study?
This clinical trial studies the following conditions: Muscle-Invasive Bladder Carcinoma.
What interventions are being tested in trial NCT04506554?
The interventions under investigation include: AMVAC + Nivolumab (DRUG).
Who is sponsoring clinical trial NCT04506554?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04506554 being conducted?
This trial has 4 study locations across North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscle-Invasive Bladder Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
RECRUITING · Phase 2
-
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
RECRUITING · Phase 2
-
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
RECRUITING · Phase 2
-
Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
RECRUITING · Phase 2
-
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.